Boston Therapeutics, Inc.
The makers of SUGARDOWN®
Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of complex carbohydrate drug design, a specialized field involving understanding the importance of the role that carbohydrates play in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement shown to moderate post-meal blood glucose; BTI-7, a new chewable dose form of the widely prescribed anti-diabetic drug metformin hydrochloride; PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation; and IPOXYN™, a systemic, injectable complex carbohydrate-based drug for prevention of necrosis and treatment of limb ischemia.
The company has submitted structure and function claims for its first consumer product trademarked SUGARDOWN. Those concerned about high blood sugar and carbohydrate intake may find SUGARDOWN an effective dietary supplement.
We want to provide effective and safe products for our customers that help them improve their health and foster a healthy lifestyle.
Company founders have extensive expertise in complex carbohydrate chemistry, manufacturing, regulatory and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration and Environmental Protection Agency. The founders also provide over 50 years of combined expertise in public and private business entities management, banking, marketing and sales.
Boston Therapeutics is a public company whose stock is traded on the OTCQB under the symbol BTHE. For more information on Boston Therapeutics, please visit the company website at bostonti.com.
Many dietary supplements have a long list of ingredients which are difficult to measure or source. Their ingredients may have possible interaction between themselves or with other supplements or with drugs. Boston Therapeutics promises you that SUGARDOWN’s proprietary chemistry is based on the philosophy of employing simplicity, quality and validation in product development and manufacturing.
While other supplements imply prevention or treatment claims by stating that they increase cell sensitivity to insulin, support insulin production, or support good pancreatic, brain, liver, blood activity, we state that SUGARDOWN is non-systemic, works in the digestive system and has no role in removing sugar from the blood by these other means. SUGARDOWN as a functional dietary supplement, has a non-systemic role to keep glucose from being released from complex carbohydrates from food during digestion.
To summarize, SUGARDOWN doesn’t remove sugar from the blood: SUGARDOWN’s non-systemic activity simply keeps blood sugar from going up considerably in the first place.
The Better Business Bureau® (BBB) has determined that Boston Therapeutics Inc. meets BBB accreditation standards, which include a commitment to make a good faith effort to resolve any consumer complaints.